A Phase 3 interventional study of OPC-14597 (Aripiprazole) in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-02-10.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing aripiprazole in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Aripiprazole · Depressive Disorder, Major.
Among the 33 studies testing aripiprazole in Depressive Disorder, Major, this one is the 18th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 3, and was the 10th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 33 studies testing aripiprazole in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:
Peking University · Sites in China
Ages 18–55
Xinyu Zhou · Sites in China
Ages 12–17
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 173 across the 33 interventional studies. Of the 26 that completed or were terminated, 17 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 26th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2009, is one of 23 in phase 3, and was the 6th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
1 of the studies testing aripiprazole in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011693Xinyu ZhouSwitching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies testing aripiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor (SNRI), in subjects with major depressive disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OPC-14597 (Aripiprazole)
administered orally once daily, 3 to 15 mg daily, 52 weeks
Montgomery-Asberg Depression Rating Scale (MADRS)
Change from baseline to Last Observation Carried Forward (LOCF). Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts
Time frame: Baseline(Day 1), Week52 or at discontinuation
| Milestone | Continuing Subjects | Newly Entering Subjects |
|---|---|---|
| Started | 122 | 33 |
| Completed | 73 | 10 |
| Not completed | 49 | 23 |
| Withdrew: Adverse event | 13 | 10 |
| Withdrew: Withdrawal by subject | 13 | 10 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Protocol violation | 7 | 2 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Physician decision | 5 | 1 |
| Withdrew: Diabetic glucose level or hba1c>=6.5% | 2 | 0 |
| Withdrew: Change of residence or other commitments | 5 | 0 |
Change from baseline to Last Observation Carried Forward (LOCF). Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts
| Rating Score | Continuing Subjects | Newly Entering Subjects |
|---|---|---|
| Montgomery-Asberg Depression Rating Scale (MADRS) | -4.60 ± 0.8 | -10.5 ± 1.9 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Continuing Subjects | — | 2/122 (1.6%) | 111/122 (91%) |
| Newly Entering Subjects | — | 4/33 (12.1%) | 29/33 (87.9%) |
| Event | Continuing Subjects | Newly Entering Subjects |
|---|---|---|
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/122 | 1/33 |
| PneumoniaInfections and infestations | 0/122 | 1/33 |
| Urinary Tract InfectionInfections and infestations | 0/122 | 1/33 |
| Femur FractureInjury, poisoning and procedural complications | 0/122 | 1/33 |
| Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/122 | 1/33 |
| ParkinsonismNervous system disorders | 0/122 | 1/33 |
| Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders | 0/122 | 1/33 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/122 | 1/33 |
| Haematoma SubduralInjury, poisoning and procedural complications | 1/122 | 0/33 |
| Abortion MissedPregnancy, puerperium and perinatal conditions | 1/122 | 0/33 |
| Event | Continuing Subjects | Newly Entering Subjects |
|---|---|---|
| NasopharyngitisInfections and infestations | 42/122 | 5/33 |
| Weight IncreasedInvestigations | 39/122 | 2/33 |
| AkathisiaNervous system disorders | 34/122 | 8/33 |
| ConstipationGastrointestinal disorders | 7/122 | 6/33 |
| SomnolenceNervous system disorders | 14/122 | 5/33 |
| ContusionInjury, poisoning and procedural complications | 3/122 | 4/33 |
| FallInjury, poisoning and procedural complications | 0/122 | 4/33 |
| InsomniaPsychiatric disorders | 6/122 | 4/33 |
| TremorNervous system disorders | 12/122 | 2/33 |
| DysgeusiaNervous system disorders | 1/122 | 3/33 |
| Age, Continuous(years) | Continuing Subjects | Newly Entering Subjects | Total |
|---|---|---|---|
| Mean | 39.1 ± 8.6 | 73.1 ± 5.6 | 46.3 ± 16.1 |
| Age, Categorical(Participants) | Continuing Subjects | Newly Entering Subjects | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 122 | 0 | 122 |
| >=65 years | 0 | 33 | 33 |
| Sex: Female, Male(Participants) | Continuing Subjects | Newly Entering Subjects | Total |
|---|---|---|---|
| Female | 55 | 23 | 78 |
| Male | 67 | 10 | 77 |
| Region of Enrollment(participants) | Continuing Subjects | Newly Entering Subjects | Total |
|---|---|---|---|
| Japan | 122 | 33 | 155 |
The record gives a start of Mar 2009, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Co., Ltd. →